Cancer Research
Overview
Cancer is the leading cause of death worldwide, causing many patients to suffer from severe pain. We strive to overcome resistance against existing cancer therapeutics and achieve the ultimate goal of conquering cancer. Extending attempts are being made to enhance the anti-tumor efficacy and expand indications for therapeutics in various cancer therapies including targeted therapy, immunotherapy, antibody therapy, and combination therapy.
In addition, we are making efforts to build a pipeline through open innovation utilizing artificial intelligence in the face of the accelerating digital transformation.
In addition, we are making efforts to build a pipeline through open innovation utilizing artificial intelligence in the face of the accelerating digital transformation.
Zoom Images
Combination therapy
- Immuno-Oncology
IL-2, CCR4
Drugs that activate the immune system in the turmor microenviroment, allowing anti-cancer immune cells to attack cancer cells more effectively.
- Targeted Oncology
RAF, MKI, EZH1/2, SOS1
Drugs that selectively attack only Cancer cells by effectively inhibiting cancer-causing mutant proteins and abnormal signaling in the cell.
- Antibodies
Bispecific antibody is designed to bind to two different epitopes, either on the same or on different targets